X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
Sudy published in PLOS ONE titled, Evidence for novel, effective approach to targeting carcinoma catabolism exploiting anti-cancer mitochondrial drug, CPI-613 multi-target, tumor-preferential inhibition of mitochondrial TCA cycle by first-in-class drug, devimistat.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
